Go Pro
Steve Seedhouse

Steve Seedhouse Analyst Performance

Equity Research- Biotechnology at Cantor Fitzgerald

Steve Seedhouse is a stock analyst at Cantor Fitzgerald in the healthcare sector, covering 17 publicly traded companies. Over the past year, Steve Seedhouse has issued 41 stock ratings, including strong buy, buy, and hold recommendations. While full access to Steve Seedhouse's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steve Seedhouse's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
45 Last 1 Years
Buy Recommendations
88.89% 40 Buy Ratings
Companies Covered
17 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy4.4%2 ratings
Buy84.4%38 ratings
Hold11.1%5 ratings
Sell0.0%0 ratings

Out of 45 total stock ratings issued by Steve Seedhouse at Cantor Fitzgerald, the majority (84.4%) have been Buy recommendations, followed by 11.1% Hold and 4.4% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
17 companies

Steve Seedhouse, an analyst at Cantor Fitzgerald, currently covers 17 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
17 companies
100.0%

Steve Seedhouse of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
12 companies
70.6%
PHARMACEUTICALS
5 companies
29.4%

Steve Seedhouse's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
8/17/2026Downgrade$4.23Neutral
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
8/12/2026Boost Price Target$174.36$270.00Overweight
InflaRx N.V. stock logo
IFRX
InflaRx
8/7/2026Boost Price Target$1.72$6.00Overweight
Innoviva, Inc. stock logo
INVA
Innoviva
8/7/2026Lower Price Target$21.11$34.00Overweight
Xencor, Inc. stock logo
XNCR
Xencor
8/6/2026Boost Price Target$19.84$44.00Overweight
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
8/6/2026Boost Price Target$5.92$12.00Overweight
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
8/6/2026Boost Price Target$12.25$55.00Overweight
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
7/8/2026Initiated Coverage$14.02$47.00Overweight
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
5/29/2026Reiterated Rating$5.79Overweight
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
5/21/2026Initiated Coverage$5.60$20.00Overweight
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
5/21/2026Initiated Coverage$5.71$20.00Overweight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
5/15/2026Reiterated Rating$41.03Neutral
Harrow, Inc. stock logo
HROW
Harrow
5/13/2026Lower Price Target$28.93$88.00Overweight
InflaRx N.V. stock logo
IFRX
InflaRx
5/11/2026Boost Price Target$2.69$4.00Overweight
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
5/5/2026Initiated Coverage$4.59$7.00Overweight
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4/30/2026Lower Price Target$31.33$100.00Overweight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
3/31/2026Downgrade$40.39Hold
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3/30/2026Initiated Coverage$4.35$15.00Overweight
Surrozen, Inc. stock logo
SRZN
Surrozen
3/24/2026Reiterated Rating$24.82$40.00Overweight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
3/18/2026Lower Price Target$18.36$31.00Overweight
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
3/6/2026Reiterated Rating$4.57Overweight
Harrow, Inc. stock logo
HROW
Harrow
3/4/2026Lower Price Target$38.60$91.00Overweight
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
3/3/2026Boost Price Target$172.27$266.00Overweight
Surrozen, Inc. stock logo
SRZN
Surrozen
2/19/2026Initiated Coverage$25.09$40.00Overweight
Surrozen, Inc. stock logo
SRZN
Surrozen
2/19/2026Initiated Coverage$26.93$40.00Overweight
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2/5/2026Boost Price Target$13.86$41.00Overweight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
1/13/2026Lower Price Target$23.20$35.00Overweight
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
12/11/2025Reiterated Rating$5.43Overweight
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
12/9/2025Boost Price Target$18.52$34.00Overweight
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
11/24/2025Initiated Coverage$120.56$154.00Overweight
Korro Bio, Inc. stock logo
KRRO
Korro Bio
11/13/2025Downgrade$31.42Neutral
Harrow, Inc. stock logo
HROW
Harrow
11/11/2025Reiterated Rating$38.74$94.00Overweight
Xencor, Inc. stock logo
XNCR
Xencor
11/6/2025Boost Price Target$14.78$42.00Overweight
Innoviva, Inc. stock logo
INVA
Innoviva
11/6/2025Boost Price Target$19.87$31.00Overweight
89BIO stock logo
ETNB
89BIO
10/31/2025Reiterated Rating$14.84Overweight
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
10/27/2025Reiterated Rating$7.36$12.00Overweight
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
10/13/2025Downgrade$6.21Neutral
Xencor, Inc. stock logo
XNCR
Xencor
10/8/2025Upgrade$12.40Strong-Buy
Xencor, Inc. stock logo
XNCR
Xencor
10/6/2025Reiterated Rating$12.07$40.00Overweight
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
10/2/2025Set Price Target$2.98$7.00Overweight
Major Buy Alert Issued for August 31st (Ad)

Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of August 31st. See which stocks his AI research platform is flagging right now.tc pixel

See which stocks his AI research platform is flagging now
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
10/2/2025Upgrade$3.00$7.00Strong-Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
8/1/2025Boost Price Target$23.27$40.00Overweight
Innoviva, Inc. stock logo
INVA
Innoviva
7/11/2025Initiated Coverage$19.06$26.00Overweight
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
7/11/2025Initiated Coverage$22.67$52.00Overweight
Harrow, Inc. stock logo
HROW
Harrow
7/11/2025Initiated Coverage$31.37$76.00Overweight